Skip to content


World Allergy Organization Journal

Open Access

Reactivity of the contact tests (patch test) in elderly patients compared to non-elderly at the allergy clinic of the Policlínica Geral do Rio de Janeiro

  • Luiz Carlos Arcanjo1
World Allergy Organization Journal20158:714

Published: 8 April 2015


Senility often brings with it a series of changes in the immune system (immunosenescence) which may affect, among other areas, the lymphocyte-mediated response. The objective of this research was to evaluate the influence of immunosenescence on cellular response in patients submitted to contact patch test at the Allergy Clinic of Policlínica Geral do Rio de Janeiro.


Retrospective analysis of patients submitted to contact test from january 2012 to june 2014, comparing the group of elderly (over 60 years) and the non-elderly group. The results were statistically analyzed using the SPSS stastitic software.


Two hundred and thirty six patients were submitted to contact test. Seventy five (31.8%) elderly (> 60 years) and 161 (68.2%) non-elderly (10-59 years). Among elderly, 46 (62.7%) had positive tests, and 29 (37.3%) negative tests. In non-elderly , 112 (69.6%) had positive and 49 (30.4%) negative tests. Despite the difference in positivity between elderly and non-elderly patients, the result was not statistically significant by Chi-square test (p = 0.366). The most frequent sensitizers in the elderly group were fragance-mix (31,9%), Euxyl K – 400 (23,4%), cobalt chloride (23,4%), imidazole derivates (21,3%) and nickel sulfate (21,3%); in the non-elderly group the most frequent contact allergens were nickel sulfate (42,9%), cobalto chloride (42,9%), fragance-mix (26,8%) and imidazole derivate (16,1%). In elderly group, four pacients were over 80 years old, including two positive tests.


The immune response to contactants seems not to be affected by immunosenescence. Therefore, contact tests should be considered in this age group.

Authors’ Affiliations

Policlinica Geral Do Rio De Janeiro, Brazil


© Arcanjo; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.